Literature DB >> 12807397

Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.

K Yasui, K Nakaso, H Kowa, T Takeshima, K Nakashima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12807397     DOI： 10.1034/j.1600-0404.2003.00135.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


× No keyword cloud information.
  10 in total

Review 1.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

2.  The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.

Authors:  E Nissinen; H Nissinen; H Larjonmaa; A Väänänen; T Helkamaa; I Reenilä; P Rauhala
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

3.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

4.  Vitamin B12-impaired metabolism produces apoptosis and Parkinson phenotype in rats expressing the transcobalamin-oleosin chimera in substantia nigra.

Authors:  Carlos Enrique Orozco-Barrios; Shyue-Fang Battaglia-Hsu; Martha Ligia Arango-Rodriguez; Jose Ayala-Davila; Celine Chery; Jean-Marc Alberto; Henry Schroeder; Jean-Luc Daval; Daniel Martinez-Fong; Jean-Louis Gueant
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

5.  Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.

Authors:  Martin Nevrly; Petr Kanovsky; Hana Vranova; Katerina Langova; Petr Hlustik
Journal:  Neurol Sci       Date:  2010-05-13       Impact factor: 3.307

Review 6.  Current status of symptomatic medical therapy in Parkinson's disease.

Authors:  Stewart A Factor
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

7.  Molecular Effects of L-dopa Therapy in Parkinson's Disease.

Authors:  Jolanta Dorszewska; Michal Prendecki; Margarita Lianeri; Wojciech Kozubski
Journal:  Curr Genomics       Date:  2014-02       Impact factor: 2.236

8.  Hyperhomocysteinemia in patients with Parkinson's disease and relationship to vitamin B level.

Authors:  Hae-Won Shin; Young Ho Sohn
Journal:  J Mov Disord       Date:  2009-04-30

9.  A coumarin-based fluorescent probe as a central nervous system disease biomarker.

Authors:  Ann-Chee Yap; Ummi Affah Mahamad; Shen-Yang Lim; Hae-Jo Kim; Yeun-Mun Choo
Journal:  Sensors (Basel)       Date:  2014-11-10       Impact factor: 3.576

10.  Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and L-Dopa Treatment.

Authors:  Agata Rozycka; Pawel P Jagodzinski; Wojciech Kozubski; Margarita Lianeri; Jolanta Dorszewska
Journal:  Curr Genomics       Date:  2013-12       Impact factor: 2.236
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.